Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer

International Journal of Clinical Oncology
Susumu OkanoMakoto Tahara

Abstract

In treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN), the use of docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by high-dose cisplatin chemoradiotherapy (CRT) carries concerns over toxicity. We evaluated the feasibility of TPF as induction chemotherapy (IC) to Japanese patients and the tolerability of CRT with fractionated administration of cisplatin after IC. Patients with unresectable stage III, IV SCCHN received IC followed by CRT. IC consisted of three 3-week cycles of docetaxel 70-75 mg/m2 on day 1, cisplatin 70-75 mg/m2 on day 1, and 5-fluorouracil 750 mg/m2 on days 1-5. Patients subsequently received IMRT concomitant with fractionated administration of cisplatin (20 mg/m2) on days 1-4, repeated every 3 weeks. The primary endpoint was completion of the three cycles of IC. Forty-eight patients were enrolled. The IC treatment completion rate was 85%. Grade 3-4 toxicities of TPF were neutropenia (79%) and febrile neutropenia (15%). Thirty-eight patients (79%) achieved a response after IC. Forty patients subsequently underwent CRT. Thirty-three patients (83%) completed the planned cycles of fractionated administration of cisplatin, but seven (18%) did not. Grade 3-4 toxicities during ...Continue Reading

References

Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J AdelsteinArlene A Forastiere
Dec 3, 2003·The New England Journal of Medicine·Arlene A ForastiereJay Cooper
Nov 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Kian Ang
Oct 26, 2007·The New England Journal of Medicine·Jan B VermorkenUNKNOWN EORTC 24971/TAX 323 Study Group
Oct 26, 2007·The New England Journal of Medicine·Marshall R PosnerUNKNOWN TAX 324 Study Group
Mar 26, 2009·Journal of the National Cancer Institute·Yoann PointreauGilles Calais
May 19, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jean-Pierre PignonUNKNOWN MACH-NC Collaborative Group
Jan 24, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean Louis LefebvreEtienne Bardet
Nov 22, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R HittUNKNOWN Spanish Head and Neck Cancer Cooperative Group (TTCC)
Mar 22, 2014·Current Opinion in Oncology·Milena P Mak, Bonnie S Glisson
Jul 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenEverett E Vokes
Dec 15, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C M L DriessenC M L van Herpen
Jul 28, 2016·Nihon Jibiinkoka Gakkai kaiho·Katsumasa TakahashiKazuaki Chikamatsu
Sep 16, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M G GhiUNKNOWN GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

© 2022 Meta ULC. All rights reserved